The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta₂-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.1

MAINTENANCE TREATMENT — An inhaled corticosteroid is the most effective long-term treatment for control of mild, moderate, or severe persistent asthma. In randomized controlled trials, inhaled corticosteroids have been significantly more effective than long-acting beta₂-agonists, leukotriene modifiers, cromolyn, or theophylline in improving pulmonary function, preventing symptoms and exacerbations, reducing the need for emergency department treatment, and decreasing deaths due to asthma. ... more      

Would you like to read the rest of this article?  Gain access below.